Woodstock Corp’s Neurocrine Biosciences NBIX Stock Holding History

Woodstock Corp’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.21M	Hold	7,192	–	–	0.1%	99
2026 Q1	$947K	Hold	7,192	–	–	0.08%	104
2025 Q4	$1.02M	Hold	7,192	–	–	0.09%	103
2025 Q3	$1.01M	Hold	7,192	–	–	0.09%	103
2025 Q2	$904K	Sell	7,192 -317	-4%	-$36.4K	0.08%	104
2025 Q1	$830K	Hold	7,509	–	–	0.08%	103
2024 Q4	$1.02M	Hold	7,509	–	–	0.1%	100
2024 Q3	$865K	Hold	7,509	–	–	0.08%	106
2024 Q2	$1.03M	Hold	7,509	–	–	0.11%	95
2024 Q1	$1.04M	Sell	7,509 -2,670	-26%	-$365K	0.11%	97
2023 Q4	$1.34M	Hold	10,179	–	–	0.16%	91
2023 Q3	$1.15M	Hold	10,179	–	–	0.14%	93
2023 Q2	$960K	Hold	10,179	–	–	0.11%	101
2023 Q1	$1.03M	Hold	10,179	–	–	0.13%	98
2022 Q4	$1.22M	Hold	10,179	–	–	0.16%	88
2022 Q3	$1.08M	Hold	10,179	–	–	0.16%	90
2022 Q2	$992K	Hold	10,179	–	–	0.14%	94
2022 Q1	$954K	Sell	10,179 -359	-3%	-$30.4K	0.11%	99
2021 Q4	$898K	Hold	10,538	–	–	0.09%	107
2021 Q3	$1.01M	Hold	10,538	–	–	0.12%	99
2021 Q2	$1.03M	Hold	10,538	–	–	0.12%	96
2021 Q1	$1.02M	Hold	10,538	–	–	0.13%	96
2020 Q4	$1.01M	Hold	10,538	–	–	0.14%	98
2020 Q3	$1.01M	Sell	10,538 -4,342	-29%	-$502K	0.16%	91
2020 Q2	$1.81M	Hold	14,880	–	–	0.31%	68
2020 Q1	$1.29M	Hold	14,880	–	–	0.26%	73
2019 Q4	$1.6M	Hold	14,880	–	–	0.26%	76
2019 Q3	$1.34M	Hold	14,880	–	–	0.23%	81
2019 Q2	$1.26M	Hold	14,880	–	–	0.22%	84
2019 Q1	$1.31M	Hold	14,880	–	–	0.23%	81
2018 Q4	$1.06M	Hold	14,880	–	–	0.21%	82
2018 Q3	$1.83M	Sell	14,880 -1,698	-10%	-$193K	0.31%	74
2018 Q2	$1.63M	Hold	16,578	–	–	0.3%	75
2018 Q1	$1.38M	Hold	16,578	–	–	0.26%	83
2017 Q4	$1.29M	Hold	16,578	–	–	0.24%	85
2017 Q3	$1.02M	Hold	16,578	–	–	0.19%	91
2017 Q2	$763K	Hold	16,578	–	–	0.15%	100
2017 Q1	$718K	Hold	16,578	–	–	0.14%	99
2016 Q4	$642K	Sell	16,578 -3,381	-17%	-$153K	0.13%	106
2016 Q3	$1.01M	Hold	19,959	–	–	0.21%	91
2016 Q2	$907K	Buy	19,959 +4	+0%	+$184	0.19%	95
2016 Q1	$789K	Hold	19,955	–	–	0.17%	103
2015 Q4	$1.13M	Hold	19,955	–	–	0.25%	85
2015 Q3	$794K	Hold	19,955	–	–	0.18%	95
2015 Q2	$953K	Buy	+19,955	New	+$846K	0.18%	95

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Woodstock Corp's NBIX Position: Q2 2026 in Review

Woodstock Corp held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 7,192 shares worth $1.21M. The position accounts for 0.1% of the portfolio, ranked #99.

Woodstock Corp first reported a position in NBIX in Q2 2015 and has held it in 45 quarters since. The position peaked at $1.83M in Q3 2018. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Woodstock Corp held 7,192 shares of Neurocrine Biosciences worth $1.21M as of Q2 2026.
Woodstock Corp left its Neurocrine Biosciences share count unchanged in Q2 2026.
Neurocrine Biosciences made up 0.1% of Woodstock Corp's portfolio in Q2 2026, its #99 holding.
Woodstock Corp first reported a position in Neurocrine Biosciences in Q2 2015 and has held it in 45 quarters since.
Woodstock Corp's Neurocrine Biosciences position peaked at $1.83M in Q3 2018.
772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Woodstock Corp's 13F filing for Q2 2026, filed 13 Jul 2026.